some transactions involving AbbVie
Pharmacyclics - AbbVie acquired Pharmacyclics in 2015 for approximately $21 billion. This deal brought Imbruvica, a breakthrough therapy for certain types of blood cancers, fully into AbbVie’s portfolio. My benchmark
Allergan - The acquisition of Allergan by AbbVie was completed in May 2020 for a deal valued at about $63 billion. This acquisition expanded AbbVie's portfolio with a range of products, including Botox, Vraylar, Ubrelvy, and Juvederm.
Stemcentrx - AbbVie purchased Stemcentrx in 2016 for $5.8 billion upfront, with additional milestone payments potentially bringing the total deal value to $10.2 billion. This deal was aimed at expanding AbbVie’s oncology portfolio, particularly gaining the drug Rova-T (rovalpituzumab tesirine), which was under investigation for small cell lung cancer.
Mavupharma - In 2019, AbbVie acquired Mavupharma, a private biopharmaceutical company. The financial terms of this deal were not disclosed.
ASH2023 - Sheba 2.0, page-68
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |